Artificial antibody delivers nanoparticles to tumors
To help develop an effective HIV vaccine, researchers are trying to better understand how the immune systems of a small minority of HIV-infected people known as long-term non-progressors (LTNPs) contain the virus naturally. CD8+ T cells, which kill cells infected with HIV, enable LTNPs to control HIV, but it has been unclear how CD8+ T
Full Post: Well-armed immune cells help long-term non-progressors contain HIV
Antibodies that target epidermal growth factor receptor (EGFR) have proven themselves as potent anticancer drugs. Now, a team of investigators led by Shuming Nie, Ph.D., and Lily Yang, Ph.D., both at the Emory University School of Medicine and members of the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology, is aiming to capitalize on this targeting ability, using a modified anti-EGFR antibody to delivery nanoparticles into tumor cells.
Reporting its work in the journal Small, the Emory team describes its use of a so-called single-chain antibody to mimic the tumor-targeting properties of a standard anti-EGFR antibody. Standard antibodies are large biomolecules comprising two pairs of two peptide chains known as heavy and light chains. In part because of their large size, antibodies are difficult to work with and often have difficulty accessing the deeper regions of a solid tumor. To overcome these problems, the investigators built an artificial antibody comprising portions of a single heavy chain and a light chain hooked together. This construct is less than 20% of the size and weight of a full antibody, but it retains the larger molecule’s binding abilities for EGFR.
With their artificial antibody in hand, the investigators used it as a tumor-targeting agent for two types of nanoparticles-quantum dots, which can be seen using fluorescence imaging, and iron oxide nanoparticles, which can be imaged using standard magnetic resonance imaging (MRI) instruments. The Emory team attached the targeting agent to the nanoparticles using a novel linking technology they developed for this purpose.
With the two types of antibody-linked nanoparticles in hand, the investigators conducted a series of experiments to determine whether these nanoscale constructs would target tumors and whether tumor cells would take up take the antibody-nanoparticle combos. Indeed, targeted nanoparticles homed in quickly on tumors when injected into tumor-bearing mice, whereas untargeted nanoparticles accumulated primarily in the liver and spleen. The targeted nanoparticles also gained rapid entry into tumor cells, whereas the untargeted nanoparticles did not. The nanoparticles were visible using both fluorescence imaging and MRI.
This work, which was detailed in the paper “Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging,” was supported in part by the NCI Alliance for Nanotechnology in Cancer, a comprehensive initiative designed to accelerate the application of nanotechnology to the prevention, diagnosis, and treatment of cancer. Investigators from Ocean NanoTech, LLC, the Fox Chase Cancer Center, and the University of Washington in Seattle also participated in this study. An abstract of this paper is available at the journal’s Web site. View abstract
Working with a nanoparticle designed to target and image glioblastoma, a form of brain cancer, investigators at the University of Washington in Seattle have found that these same nanoparticles inhibit tumor cell invasion, one of the key events that leads to the metastatic spread of cancer. The investigators have also determined how the nanoparticles exert
Full Post: Toxin-nanoparticle combo inhibits brain cancer invasion while imaging tumors
A research team from the Massachusetts Institute of Technology (MIT)-Harvard Center for Nanotechnology Excellence has custom-designed nanoparticles that can deliver the anticancer drug cisplatin specifically to prostate cancer cells. The nanoparticles are composed of two different polymers and are decorated with a nucleic acid aptamer that binds to the tumor marker prostate-specific membrane antigen.
Full Post: Targeted nanoparticles boost platinum-based anticancer therapy
Given that cancer is a disease caused by gene mutations, cancer researchers have been striving to develop gene therapies aimed at correcting these mutations. However, these efforts have been hobbled by the difficulty in safely and efficiently delivering anticancer genes to tumors. Nanoparticles, however, may solve these delivery issues, and two recently published studies, using
Full Post: Targeted nanoparticles deliver therapeutic DNA to cancer cells
One of the hallmarks of many nanoparticle-based anticancer therapeutics and imaging agents is that they accumulate in tumors thanks to the fact that they are small enough to escape from the bloodstream through the leaky blood vessels that surround tumors. And although many if not most tumors are surrounded by leaky blood vessels, the
Full Post: Nanoparticle reports on drug delivery to breast tumors, predicts response to therapy
One of the key steps in the development of any drug or imaging agent intended for human use is measurement of the adsorption, metabolism, and excretion of the drug. Quantifying this collection of pharmacological properties, known as ADME, is a challenging and time-consuming process that is even more difficult when the drug or imaging
Full Post: Measuring nanoparticle behavior in the body using MRI